SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-019283
Filing Date
2022-05-10
Accepted
2022-05-10 16:16:19
Documents
17
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K Q1 EARNINGS RELEASE evok-8k_20220510.htm   iXBRL 8-K 39629
2 EX-99.1 evok-ex991_6.htm EX-99.1 260773
3 GRAPHIC gvexbikk3nqi000003.jpg GRAPHIC 1043
4 GRAPHIC gvexbikk3nqi000004.jpg GRAPHIC 4724
5 GRAPHIC gvexbikk3nqi000002.jpg GRAPHIC 1043
6 GRAPHIC gvexbikk3nqi000001.jpg GRAPHIC 24471
  Complete submission text file 0001564590-22-019283.txt   489723

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA evok-20220510.xsd EX-101.SCH 5705
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE evok-20220510_lab.xml EX-101.LAB 19431
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE evok-20220510_pre.xml EX-101.PRE 11591
11 EXTRACTED XBRL INSTANCE DOCUMENT evok-8k_20220510_htm.xml XML 3552
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 22909832
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences